The Patents Court of the High Court of England and Wales has ruled that two patents owned by Bio-Techne brand Advanced Cell Diagnostics (ACD) are invalid, rejecting a patent infringement lawsuit filed by Bio-Techne/ACD in the U.K. against Molecular Instruments.
The suit, filed in the U.K. in 2022, covers the same patents --1,910,572 and 2,500,439 --that are at issue in the patent infringement case that Bio-Techne recently filed against Molecular Instruments in the Unified Patent Court, a pan-European patent-dispute court.
In its decision, the court rejected the validity of the two patents, which are essential to Bio-Techne's RNAscope in situ hybridization technology.
The claim made in both the U.K. and European Union lawsuits is that Molecular Instruments' HCR 3.0 technology infringes on these patents. In both cases, Bio-Techne has sought damages and an injunction against Molecular Instruments.
